Skip to main content

Advertisement

SpringerLink
Log in

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Blocking integrin binding to fibronectin by a monoclonal antibody directed to integrin receptors induces apoptosis of proliferating endothelial cells. We report a case of grade 2 proteinuria, occurred fifteen days after the first administration of an anti-integrin monoclonal antibody associated to standard doses of carboplatin/paclitaxel and to a single dose of zoledronic acid in a patient treated in first line setting for a metastatic non small cell lung cancer. Kidney biopsy revealed a tubular damage probably associated to minimal change glomerulonephritis. Even if this patient did not receive any further dose of zoledronic acid, proteinuria reoccurred, although at a lower level when the investigational drug was reintroduced at the same dose. Renal function remained normal. The patient received two further cycles with lower doses, without recurrence of proteinuria. These findings suggest that this type of integrin antibody may induce transient urinary excretion of protein in a dose dependent manner without adversely affecting renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Avramides CJ, Garmy-Susini B, Vagner JA (2008) Integrins in agiogenesis and lymphagiogenesis. Nat Rev Cancer 8:604–617. doi:10.1038/nrc2353

    Article  Google Scholar 

  2. Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Br J Cancer 90:561–565. doi:10.1038/sj.bjc.6601576

    Article  CAS  PubMed  Google Scholar 

  3. Carlson TR, Hu H, Braren R (2008) Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice. Development 135:2193–2202. doi:10.1242/dev.016378 abstract

    Article  CAS  PubMed  Google Scholar 

  4. Magnussen A, Kasman IM, Norberg S et al (2005) Rapid access of antibodies to α5β1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 65:2712–2721. doi:10.1158/0008-5472.CAN-04-2691

    Article  CAS  PubMed  Google Scholar 

  5. Kim S, Bell K, Mousa S et al (2000) Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345–1362

    CAS  PubMed  Google Scholar 

  6. Bhaskar V, Fox M, Breinberg D et al (2008) Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 26:7–12. doi:10.1007/s10637-007-9078-z

    Article  CAS  PubMed  Google Scholar 

  7. Bhaskar V, Zhang D, Fox M et al (2007) A function blocking anti mousse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. Journal of translational research 5:1–11

    Google Scholar 

  8. Ramakrishnan V, Bhaskar V, Law DA et al (2006) Preclinical evaluation of anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5:273–286

    CAS  PubMed  Google Scholar 

  9. Barton J (2008) A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. J Clin Oncol 26 (May 20 suppl) abstr 9051

  10. Delmonte A, Del Conte G, Sessa C, et al (2008) Results from a phase ½ study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. J Clin Oncol 26 (May 20 suppl) abstr 16527

    Google Scholar 

  11. Evans T, Ramanathan RK, Yazji S et al (2007) Final results from cohort 1 of a phase II study of volociximab, an anti- α5β1 integrin antibody, in combination with gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 25 (June 20 suppl) abstr 4549

    Google Scholar 

  12. Yazji S, Bukowski R, Kondagunta V, et al (2007) Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear renal cell carcinoma. J Clin Oncol 25 (June 20 suppl) abstr 5094

    Google Scholar 

  13. Cranmer LD, Bedikian AY, Ribas A (2006) Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. J Clin Oncol 24 (June 20 suppl) abstr 8011

  14. Figlin RA, Kondagunta S, Yazji S, et al (2006) Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer. J Clin Oncol 24 (June 20 suppl) abstr 4535

    Google Scholar 

  15. Sandler A, Gray R, Perry MC (2007) Paclitaxel-carboplatin alone or with bevacizumab in non-small-cell lung cancer. N Engl J Med 355:2542–2550. doi:10.1056/NEJMoa061884

    Article  Google Scholar 

  16. Manegold C, von Pawel J, Zatloukal P (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25 (June 20 suppl) LBA 7514

  17. Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int 64:281–289. doi:10.1046/j.1523-1755.2003.00071.x

    Article  CAS  PubMed  Google Scholar 

  18. George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49:23–29. doi:10.1053/j.ajkd.2006.11.024

    Article  Google Scholar 

  19. Eremina V, Jefferson AJ, Kowalewska J (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136. doi:10.1056/NEJMoa0707330

    Article  CAS  PubMed  Google Scholar 

  20. Izzedine H (2007) Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity. Bull Cancer 94:981–986

    CAS  PubMed  Google Scholar 

  21. Zhu X, Wu S, Dahut WL et al (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186–193. doi:10.1053/j.ajkd.2006.11.039

    Article  CAS  PubMed  Google Scholar 

  22. Maesaka JK, Mittel SK, Fishabane S (1997) Paraneoplastic syndromes of the kidney. Semin Oncol 24:373–381

    CAS  PubMed  Google Scholar 

  23. Adler S, Sharma R, Savin VJ et al (1996) Alteration of glomerular permeability to macromolecules induced by cross-linking of beta 1 integrin receptors. Am J Pathol 149:987–996

    CAS  PubMed  Google Scholar 

  24. Stupp R, Goldbrunner R, Neyns B, et al (2007) Phase I/IIa trial of cilengitide (EMD 12947) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 25 (June 20 suppl) abstr 2000

  25. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomised phase II study of cilengitide, an integrin-targeting arginine-glicine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617. doi:10.1200/JCO.2008.16.7510

    Article  CAS  PubMed  Google Scholar 

  26. Delbaldo C, Raymond E, Vera K et al (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against αVβ3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26:35–43. doi:10.1007/s10637-007-9077-0

    Article  CAS  PubMed  Google Scholar 

  27. Hersey P, Soman S, O’Day et al (2005) A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alphaVbeta3 integrin + dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol 24 (June 1 suppl) abstr 7507

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France

    Andrea Gombos, Benjamin Besse, Christophe Massard, Rastislav Bahleda & Jean-Charles Soria

  2. Departement of Nephrology, La Pitié Salpetrière Hospital, Paris, France

    Hassan Izzedine

  3. Department of Pathology, La Pitié Salpetrière Hospital, Paris, France

    Isabelle Brocheriou

Authors
  1. Andrea Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hassan Izzedine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Besse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christophe Massard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabelle Brocheriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rastislav Bahleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Charles Soria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Gombos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gombos, A., Izzedine, H., Besse, B. et al. Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Invest New Drugs 28, 102–105 (2010). https://doi.org/10.1007/s10637-009-9247-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9247-3

Keywords

Search

Navigation